LINK BETWEEN PROSTATE CANCER PROGNOSTICATION AND PROSTATE-SPECIFIC ANTIGEN DENSITY AMONG PAKISTANI PEOPLE’S
Main Article Content
Keywords
Prostate specific antigen density, Gleason score, Digital rectal examination, cancer.
Abstract
Background: Prostate specific antigen density has been displayed as an important gizmo for prostate cancer diagnostics and prognostication.
Materials and Methods: The research was a logical cross-sectional study including 470 patients at Mekran Medical College/ Teaching Hospital with prostate specific antigen levels of > 4.0 ng/ml and typical or abnormal rectal examination findings. Prostate Specific Antigen Density was figured and transrectal ultrasound guided prostate biopsies were performed. Statistical examination was performed utilizing a SPSS version 20. Suitable test measurements including mean, standard deviation, Chi-square, t-test, Fischer's careful test, Pearson's r-test) with p-value < 0.05 considered as significant.
Results: The mean age for the patients was 55.7 + long term while the mean ages of 52.9 + 3.3 years and 65.1 + 11.3 years were for patients with non-cancer and malignant prostate lesion separately. 26.2 % were adenocarcinomas. The mean and median of Prostate Specific Antigen Density for prostate cancer were 0.31 + 0.23 and 0.31 ng/mL/cm individually. Prostate Specific Antigen Density had positive prognosticating relationship with prostate cancer risk (p=0.004) utilizing univariate logistic regression. The Area Under the Curve (AUC) and optimal cutoff point for the density was 0.9 (95% CI: 0.83-0.97) and 0.052 separately, showing solid diagnostic execution for prognosticating prostate cancer. Prostate Specific Antigen Density showed statistical significant in cancer detection (p < 0.001) with a sensitivity and false positive rate of 90.0 %, 85.0 % and 8.0 % separately.
Conclusion: A Prostate Specific Antigen Density of 0.052 ng/ml/cm can be used as a cut-off value to prognosticating prostate cancer when evaluating patients with raised Prostate Specific Antigen in Pakistani population.
References
2. Abonyo C., Ndaguatha P, Owillah FA. To assess the correlation between prostate specific antigen density and prostate biopsy results of patients with raised prostatic specific antigen levels at the Kenyatta National Hospital. East African Medical Journal.2020; 97(8):2975-2982.
3. Munteanu VC, Munteanu RA, Gulei D, Schitcu VH, Petrut B, Berindan Neagoe I, Achimas Cadariu P, Coman I. PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer. Diagnostics (Basel).2020;10:806.
4. Okuja M, Ameda F, Dabanja H, Bongomin F, Bugeza S. Relationship between serum prostate specific antigen and transrectal prostate sonographic findings in asymptomatic Ugandan males. African Journal of Urology.2021;27:e58.
5. Ikuerowo SO, Omisanjo OA, Bioku MJ, Ajala MO, MordiVP, EshoJO. Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination. Pan Afr Med.J.2013; 15:129.
6. Ogbetere FE, Irekpita E. Detection rate of prostate cancer following 12-core extended biopsy in a Semi-urban Nigerian Tertiary Hospital. Urology Annals.2021;13:150-155.
7. Soronen V, Talala K, Raitanen J, Taari K, Tammela T, Auvinen A. Digital rectal examination in prostate cancer screening at PSAlevel 3.0-3.9 ng/ml: long-term results from a randomized trial. Scand J Urol. 2021;55(5):348-353.
8. Beyer K, Moris L, Lardas M, Haire A, Barletta F, Scuderi S, et al. Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. BMJ Open. 2021;11:e040531.
9. Mensah JE, Akpakli E, Kyei M, Klufio K, Asiedu I, Asante K, et al. Prostate-specific antigen, digital rectal examination, and prostate cancer detection: Astudy based on more than 7000 transrectal ultrasound-guided prostate biopsies in Ghana. Translational Oncology;2024; 51:102163.
10. Ying Y, He W, Xiong Q, Wang Z, Wang M, Chen Q, et al. Value of digital rectal examination in patients with suspected prostate cancer: a prospective cohort analysis study. Transl Androl Urol.2023;12(11):1666-1672.
11. Zhu J, Wu X, Xue Y, Li X, Zheng Q, Xue X, et al. Prospective analysis of the diagnostic accuracy of digital rectal examination and magnetic resonance imaging for T staging of prostate cancer. J Cancer Res Ther. 2023;19(4):1024-1030.
12. Sarkar D, Jain P, Gupta P, Pal DK. Correlation of digital rectal examination and serum prostate-specific antigen levels for detection of prostate cancer: Retrospective analysis results from a tertiary care urology center. J Cancer Res Ther. 2022;18(6):1646-1650.
13. Elijah A. Udoh, Okon E. Akaiso, Albert E. Uk pong. Accuracy of digital rectal examination to diagnose prostate cancer confirmed by needle biopsy reports: A 3–year hospital-based study. Ibom Medical Journal.2020;13(3):156-163.
14. Bouras, S. Digital rectal examination in prostate cancer screening: a critical review of the ERSPC Rotterdam study. Afr J Urol. 2023;30, 51:1-6.
15. Morote J, Paesano N, Picola N, Muñoz-Rodriguez J, Ruiz-Plazas X, Muñoz-Rivero MV, et al. The Role of Digital Rectal Examination for Early Detection of Significant Prostate Cancer in the Era of Magnetic Resonance Imaging. Life. 2024; 14(11):1359.
16. Matsukawa A, Yanagisawa T, Bekku K, Parizi MK, Laukhtina E, Klemm J, et al. Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: a systematic review and meta-analysis. European Urology Oncology. 2024; 7 (4):697-704.
17. Krilaviciute A, Becker N, Lakes J, Radtke JP, Kuczyk M, Peters I, et al.. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer. European Urology Oncology, 2023; 6(6):566-573.
18. Aisuodionoe-Shadrach OI, Eniola SB, Nwegbu MM, Kolade-Yunusa HO, Okereke OO, Yunusa T. Determination of Serum Prostate Specific Antigen Levels Amongst Apparently Healthy Nigerian Males in a University and University Hospital Community in the Federal Capital Territory. Cancer Control.2022; 29:10732748221081366.
19. Mumuni S, O'Donnell C, Doody O. The Risk Factors and Screening Uptake for Prostate Cancer: A Scoping Review. Healthcare(Basel).2023;11(20):2780
20. Cirulli GO, Davis M, Stephens A, Chiarelli G, Finati M, Corsi N, et al. Impact of Prostate-Specific Antigen Screening Pattern on Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White Men: A Large, Urban Health System Cohort Analysis. J Urol. 2024;212(4):560-570.
21. Hamdy FC. Prostate-Specific Antigen Testing for Prostate Cancer Screening-Is the Message Getting Through? JAMA Oncol. 2022; 8(1):47-49.
22. Narain TA, Sooriakumaran P. Beyond Prostate Specific Antigen: New Prostate Cancer Screening Options. World J Mens Health. 2022;40(1):66-73.
23. Ko, YH, Kim BH, Jung W, Ha JY, Shin TJ, Kwon SY, et al. Delaying a Biopsy With Serial Prostate-Specific Antigen Checkup Helps to Identify a Significant Prostate Cancer: A Strategy to Evade UnnecessaryProcedures.JUrolOncol.2022;20(3):177-185.
24. Tidd Johnson A, Sebastian SA, Co ELF, Afaq M, Kochhar H, Sheikh M, et al. Prostate cancer screening: continued controversies and novel biomarker advancements. Curr Urol. 2022;1–10.
25. Ngwu PE, Achor GO, Eziefule VU, Orji JI, Alozie FT. Correlation between Prostate Specific Antigen and Prostate Biopsy Gleason Score. Annals of Health Research. 2019; 5:243-248.
26. Chang TH, Lin WR, Tsai WK, Chiang PK, Chen M, Tseng JS, et al. Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males was with PSA< 20 ng/ml. BMC Urol.2020;20(1):151.
27. Park DH, Yu JH. Prostate-specific antigen density as the best predictor of low- to intermediate-risk prostate cancer: a cohort study. Transl Cancer Res 2023;12(3):502-514.
28. Erdogan A, Polat S, Keskin E, Turan A. Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA2.5-10 ng/mL and 10.1-30 ng/mL? Aging Male. 2020;23(1):59-65.
29. Zou BZ, Wen H, Luo HJ, Luo WC, Xie QT, Zhou MT. Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer. Ir J Med Sci. 2023;192(6): 2681-2687.
30. Zhang Q, Li H, Song Z, Kong S, Zhao S, Fan S, Qin F, Ma J. Potential diagnostic value of multiple indicators combined with total prostate-specific antigen in prostate cancer. J Int Med Res. 2023;51(10):3000605231204429.
31. Omri N, Kamil M, Alexander K, Alexander K, Edmond S, Ariel Z, et al. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume. Prostate2020;80(16):1444-1449.
32. Nath C, Barman B, Phukan P, Sailo SL, Dey B, Nath I, et al, Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma. Journal of Laboratory Physicians. 2020;12(1):44-48.
33. Yusim I, Krenawi M, Mazor E, Novack V, Mabjeesh NJ. The use of prostate specific antigen density to predict clinically significant prostate cancer. Sci Rep.2020;10(1):20015.
34. Arafa MA, Farhat KH, Rabah DM, Khan FK, Mokhtar A, Al-Taweel W. Prostate-specific Antigen Density as a Proxy for Predicting Prostate Cancer Severity: Is There Any Difference between Systematic and Targeted Biopsy? Saudi J Med Med Sci.2023;11(4):299-304.
35. Drevik J, Dalimov Z, Uzzo R, Danella J, Guzzo T, Belkoff L, et al. Utility of PSA density in patients with PI-RADS 3 lesions across a large multi-institutional collaborative. UrolOncol.2022;40(11):490.e1-490.e6.
36. Rajendran I, Lee KL, Liness Thavaraja L, Barrett T. Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making, British Journal of Radiology. 2024; 97(1153):113–119.
37. Avci S, Çağlayan V, Önen E, Kiliç M,Gül A, Öner S. The effectiveness of prostate specific antigen density in predicting prostate cancer and clinically significant prostate cancer in patients aged 70 year sandover. Turkish Journal of Geriatrics.2020;23(2):197-205.
38. Zou, BZ., Wen, H., Luo, HJ. et al. Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer. Ir J Med Sci. 2023;192:2681–2687.
39. Danacioglu, YO, Keser, F, Efiloğlu, Ö, Culpan, M., Polat, S., Atis, R. G., & Yildirim, A. The efficiency of prostate-specific antigen density measurement using three different methods on the prediction of biochemical recurrence. The Aging Male.2021;24(1):15–23.
40. Presti JC Jr, Hovey R, Carroll PR, Shinohara K. Prospective Evaluation of Prostate Specific Antigen and Prostate Specific Antigen Density in the Detection of Non palpable and Stage T1C Carcinoma of the Prostate. Journal of Urology [Internet]. 2024;156(5):1685–90.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Muhammad Wasif Saleem
Assistant Professor, Department of Pathology, Mekran Medical College, Turbat, Pakistan.
Shomaila Ameer Alam
Assistant Professor, Department of Pathology, Mekran Medical College, Turbat, Pakistan.
Taqia Fouzia
Assistant Professor, Department of Pathology, SMBBMU lyari, Pakistan.
Afshan Iftikhar
Associate Professor, Department of Physiology, Rehman Medical College, Peshawar, Pakistan.
Syed Inayat Ali
Professor, Department of Anatomy, Baqai Medical College, karachi, Pakistan.
Shazia Hashmat
Associate Professor, Department of Physiology, Ziauddin Medical College, Karachi, Pakistan.
Syeda Zehra Ahmed
Assistant Professor, Department of Pathology, Ziauddin Medical College, Karachi, Pakistan.